MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today ...

First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data ...

US-based NeuroPace has reported the initial primary endpoint one-year outcomes from the two-year NAUTILUS trial of the RNS System for treating individuals with drug-resistant idiopathic generalised ...

NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic ...

Tuesday saw UBS begin coverage on NeuroPace Inc (NASDAQ:NPCE), a medical technology company specializing in responsive neuromodulation systems for epilepsy treatment. Analysts at UBS have given the ...

NeuroPace aims to improve the lives of epilepsy patients with its remote monitoring system. The company's RNS system offers personalized and real-time treatments for epilepsy patients. NeuroPace has ...

MOUNTAIN VIEW, Calif. - NeuroPace, Inc. (NASDAQ:NPCE), a $529 million market cap medical device company whose stock has surged over 47% in the past six months, has submitted a Premarket Approval ...

Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy 1 Long-term seizure reduction with a median reduction of 82 ...

MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, ...